ERBB2 and cancer: Using a first-generation CAR, Yasukawa et al. fused the CD16 ECD and a CD3ζ TM domain and signalling module, generating modified T cells that responded to cancer cells labelled with antibodies targeting CD20, HER2, or CCR4 in vitro and in vivo [43,70].